« Return to News | Drug Sponsors

Cephalon rejects buyout, Valeant remains committed

Wednesday, April 6, 2011 11:52 AM

U.S.-based Cephalon has rejected Canadian-based Valeant Pharmaceuticals International's takeover bid, saying that the $5.7 billion offer, or $73.00 per share, is not in the best interests of shareholders, according to Pharma Times.

Cephalon states they have "one of the broadest pipelines in the industry, with 10 late-stage product candidates targeted at novel and 'best-in-class' therapeutics." This includes six indications "with blockbuster potential which are projected to begin launching in the next three years" and these programs "represent tremendous value that is not reflected in Valeant's current proposal."

Valeant chief executive Michael Pearson responded by saying that "while we are disappointed with the response from Cephalon's board, we remain committed to our process." This includes "trying to find a modest amount of additional value if Cephalon engages with us and allows us to conduct due diligence, which we believe would take only 2-3 weeks."

Pearson also claimed to have received "positive feedback from many of the largest stockholders of Cephalon" and "we stand ready to quickly commence and close our transaction as proposed, unless Cephalon stockholders do not support our offer, in which case we will focus our attention on other opportunities to invest our capital."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.